Bactroban contains mupirocin, an antibiotic. It has bacteriostatic properties at minimum inhibitory concentrations and bactericidal properties at the higher concentrations reached when applied locally

A liquid bath additive containing 84.75% w/w soya oil.

A cream containing urea 5% and ceramide.

A liquid bath additive containing 82.95% w/w soya oil and 15% w/w lauromacrogols.

A cream containing 5% w/w urea and 3% w/w lauromacrogols.

Quick-drying, non-greasy and non-sticky medical silicone gel enriched with vitamin E. Forms an invisible matte finish, making it particularly suitable for use on the face or under cosmetic camouflage. Can be applied in a single smooth motion. Also available with SPF 40 UV protection for scars exposed to sunlight.

A 1.2 mm thick, transparent, self-adhesive medical silicone sheet for the treatment and prevention of abnormal scars. Washable and reusable and can be worn under clothing or in combination with compression therapy. For optimal results, it should be worn for 12–23 hours per day.

Ultra-thin (0.3 mm), flexible, self-adhesive and transparent medical silicone sheet for the treatment and prevention of abnormal scars. Designed for continuous wear for up to 7 days. After removal, the skin should be cleansed and a new sheet applied if continued treatment is required.

Baricitinib is a selective and reversible inhibitor of Janus kinase (JAK)1 and JAK2. In isolated enzyme assays, baricitinib inhibited the activities of JAK1, JAK2, Tyrosine Kinase 2 and JAK3 with IC50 values of 5.9, 5.7, 53 and > 400 nM, respectively. Janus kinases (JAKs) are enzymes that transduce intracellular signals from cell surface receptors for a number of cytokines and growth factors involved in haematopoiesis, inflammation and immune function. Within the intracellular signalling pathway, JAKs phosphorylate and activate signal transducers and activators of transcription (STATs), which activate gene expression within the cell. Baricitinib modulates these signalling pathways by partially inhibiting JAK1 and JAK2 enzymatic activity, thereby reducing the phosphorylation and activation of STATs.

Moisturising emollient ointment containing 50% w/w liquid paraffin BP and 50% w/w white soft paraffin.